STAT+: Trump’s drug-pricing deals set to be tested by new product launches

WASHINGTON — The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.

Briefly, those deals require companies to launch new drugs in the U.S. at net prices roughly equal to those in other wealthy nations, though the precise terms are secret. Three prescription medicines that are set to launch in the coming months will provide the most public view yet of the practical impacts of Trump’s dealmaking.

The drugs are Baxfendy for hypertension from AstraZeneca, the insulin Awiqli from Novo Nordisk, and Veppanu, a cancer drug developed by Arvinas and Pfizer that’s set to be licensed to Rigel Pharmaceuticals. Baxfendy and Veppanu aren’t yet available in other wealthy countries that are used as comparisons for reference pricing.

Continue to STAT+ to read the full story…

المصدر: STAT News